Trimethoprim Tablet Dosing
For uncomplicated urinary tract infections in adults, trimethoprim 200 mg twice daily for 5 days is the recommended dose, while prophylaxis requires 100 mg once daily at bedtime, and patients with creatinine clearance below 30 mL/min should receive half the usual dose. 1
Treatment Dosing for Acute Uncomplicated Cystitis
Women
- Standard dose: 200 mg twice daily (b.i.d.) for 5 days 1
- Trimethoprim is listed as an alternative agent (not first-line) in the 2024 European Association of Urology guidelines
- Important contraindication: Avoid in first trimester of pregnancy 1
Men
- For men with UTI, trimethoprim-sulfamethoxazole (160/800 mg b.i.d. for 7 days) is preferred over trimethoprim alone 1
- Trimethoprim monotherapy dosing for men is not specifically addressed in current guidelines
Prophylaxis Dosing for Recurrent UTIs
For prevention of recurrent infections:
- 100 mg once daily (typically at bedtime) 2
- Alternative: 40 mg trimethoprim (as part of TMP/SMX 40/200 mg) once daily or three times weekly 3
- Postcoital prophylaxis option: 40-80 mg trimethoprim (as TMP/SMX) once after intercourse 3
The 100 mg daily dose has demonstrated significant efficacy, reducing recurrence rates from 26/100 months to 3.3/100 months during prophylaxis 2.
Renal Dose Adjustment
Critical dosing modifications for impaired renal function:
| Creatinine Clearance | Dose Adjustment |
|---|---|
| >30 mL/min | Standard dose (no adjustment needed) |
| 15-30 mL/min | 50% of usual dose |
| <15 mL/min | Use not recommended [4,5] |
Important Considerations for Renal Impairment
- Trimethoprim and sulfamethoxazole disposition remains stable until CrCl drops below 30 mL/min 5
- Below this threshold, drug accumulation occurs and toxicity risk increases
- Monitor serum creatinine, potassium, and sodium closely in patients with any degree of renal impairment
Critical Safety Warnings
Electrolyte Disturbances
Trimethoprim carries significant risk of hyperkalemia and hyponatremia through inhibition of distal tubular Na+/K+-ATPase 6:
- Dose-dependent effect: Daily doses >160 mg significantly increase risk
- Hyperkalemia cumulative incidence: 29.4% with doses >160 mg/day vs. 6.7% with ≤160 mg/day 6
- Hyponatremia cumulative incidence: 64.7% with doses >160 mg/day vs. 35.2% with ≤160 mg/day 6
High-Risk Populations Requiring Extra Caution
Avoid or use extreme caution in patients taking:
- Renin-angiotensin system (RAS) blockers (ACE inhibitors, ARBs)
- Potassium-sparing diuretics (especially spironolactone)
- In patients on RAS blockers + spironolactone: trimethoprim causes 18 additional cases of hyperkalemia per 1000 UTIs treated compared to amoxicillin 7
Acute Kidney Injury Risk
- Trimethoprim increases odds of acute kidney injury by 72% compared to amoxicillin (adjusted OR 1.72,95% CI 1.31-2.24) 7
- Results in 2 additional hospital admissions for AKI per 1000 UTIs treated in general population 7
- Risk increases to 11 additional AKI admissions per 1000 UTIs in patients on RAS blockers + spironolactone 7
Monitoring Requirements
When prescribing trimethoprim, particularly at doses >160 mg/day:
- Baseline: Serum creatinine, potassium, sodium
- During therapy: Monitor electrolytes if treatment duration exceeds 5-7 days
- High-risk patients: Consider alternative antibiotics (nitrofurantoin, fosfomycin) if on RAS blockers or potassium-sparing diuretics
Clinical Context
Trimethoprim is not a first-line agent for uncomplicated cystitis in women according to 2024 EAU guidelines 1. First-line options include fosfomycin trometamol (3g single dose), nitrofurantoin, or pivmecillinam. Trimethoprim should be reserved for situations where first-line agents are contraindicated or unavailable, and only when local E. coli resistance patterns are <20% 1.
The drug's propensity to cause reversible increases in serum creatinine (through inhibition of tubular creatinine secretion) can confound assessment of true renal function 6. An elevated creatinine during trimethoprim therapy should prompt evaluation for both true AKI and electrolyte abnormalities.